The global central nervous system therapeutics market size was USD 107.33 billion in 2023, estimated at USD 116.88 billion in 2024 and is anticipated to reach around USD 267.62 billion by 2034, expanding at a CAGR of 8.64% from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Central Nervous System Therapeutic Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Central Nervous System Therapeutic Market, by Disease Type, 2024-2034
8.1.1. Neurovascular Diseases
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Mental Health
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Neurodegenerative Diseases
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. CNS Trauma
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. CNS Cancer
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Infectious Diseases
8.1.6.1. Market Revenue and Forecast (2021-2034)
8.1.7. Others
8.1.7.1. Market Revenue and Forecast (2021-2034)
9.1. North America
9.1.1. Market Revenue and Forecast, by Disease (2021-2034)
9.1.2. U.S.
9.1.3. Rest of North America
9.1.3.1. Market Revenue and Forecast, by Disease (2021-2034)
9.2. Europe
9.2.1. Market Revenue and Forecast, by Disease (2021-2034)
9.2.2. UK
9.2.2.1. Market Revenue and Forecast, by Disease (2021-2034)
9.2.3. France
9.2.3.1. Market Revenue and Forecast, by Disease (2021-2034)
9.2.4. Rest of Europe
9.2.4.1. Market Revenue and Forecast, by Disease (2021-2034)
9.3. APAC
9.3.1. Market Revenue and Forecast, by Disease (2021-2034)
9.3.2. India
9.3.2.1. Market Revenue and Forecast, by Disease (2021-2034)
9.3.3. China
9.3.3.1. Market Revenue and Forecast, by Disease (2021-2034)
9.3.4. Japan
9.3.4.1. Market Revenue and Forecast, by Disease (2021-2034)
9.3.5. Rest of APAC
9.3.5.1. Market Revenue and Forecast, by Disease (2021-2034)
9.4. MEA
9.4.1. Market Revenue and Forecast, by Disease (2021-2034)
9.4.2. GCC
9.4.2.1. Market Revenue and Forecast, by Disease (2021-2034)
9.4.3. North Africa
9.4.3.1. Market Revenue and Forecast, by Disease (2021-2034)
9.4.4. South Africa
9.4.4.1. Market Revenue and Forecast, by Disease (2021-2034)
9.4.5. Rest of MEA
9.4.5.1. Market Revenue and Forecast, by Disease (2021-2034)
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Disease (2021-2034)
9.5.2. Brazil
9.5.2.1. Market Revenue and Forecast, by Disease (2021-2034)
9.5.3. Rest of LATAM
9.5.3.1. Market Revenue and Forecast, by Disease (2021-2034)
10.1. Biogen Inc.
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Otsuka Pharmaceutical Co. Ltd
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Eli Lilly and Company
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Merck & Co.
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. AstraZeneca
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Takeda Pharmaceutical Company Limited
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Novartis AG
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. Teva Pharmaceutical Industries Ltd.
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
12.1. About Us
12.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample